IP Library › Granted Patent US 12,091,414
Granted Patent B2
US 12,091,414 · App. 17/427,357 · Granted Sep 17, 2024

Crystalline form of Di-p-toluoyl-L-tartrate of upadacitinib

Inventors: Peng Wang (Suzhou, CN); Pixu Li (Suzhou, CN); Qiang Wei (Suzhou, CN); Wen Cheng (Suzhou, CN)
Assignee: SUZHOU PENGXU PHARMATECH CO., LTD.
C07D487/14C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,091,414
App. No.
17/427,357
Granted
Sep 17, 2024
Kind
B2
Abstract

The present application provides a upadacitinib salt compound and a preparation method therefor. The salt involved in the method in the present application has an easy preparation operation, a cheap raw material easy to get, and a good purification effect on upadacitinib, and is beneficial to industrial production.

Claims (3)

1. Crystalline Form A of Di-p-toluoyl-L-tartrate of a compound of formula I:

characterized by a X-ray powder diffraction pattern comprising peaks at 3.9, 7.5, 10.4, 13.4, 15.2, and 23.4°±0.2 2θ degrees.

2. A pharmaceutical composition comprising the di-p-toluoyl-L-tartrate of claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2021
From: WANG, PENG; LI, PIXU; WEI, QIANG; CHENG, WEN
To: SUZHOU PENGXU PHARMATECH CO., LTD.
Reel/Frame 057034/0451 →
Priority Claims (1)
CN 201910385804.0 · May 9, 2019 · national
Continuity (1)
Related Publication 20220041611A1 · Feb 10, 2022